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Summary
 Background The biological effectiveness of elevated temperature (hyperthermia) on cancer 
cells is a well documented issue. Nevertheless, it is still not widely used in clini-
cal practice, mainly due to technical difﬁ culties. The main limiting factor is the 
protection of healthy tissue during the hyperthermia procedure. Hyperthermia, 
used as an adjuvant treatment with brachytherapy, provides the possibility of low-
ering total radiation doses, without reducing biological effects.
 Aim The aim of this work was to present the advantages of using 500 kHz hyperther-
mia in HDR brachytherapy of cervical & endometrial cancer.
 Materials/Methods Hyperthermia procedures were performed in 8 endometrial cancer patients and 
2 cervical cancer patients with early recurrent local disease in previously irradiat-
ed areas. One or two interstitial hyperthermia procedures were performed using 
rigid metal needles, both for brachytherapy and temperature elevation. The to-
tal radiation dose was 30 Gy, delivered in 3 or 6 Gy per fraction. In the case of 3 
Gy per fraction, a scheme of two fractions per day, separated by at least 8 hours, 
was used. The total treatment time ranged from 5 to 14 days. Hyperthermia was 
performed concurrently with brachytherapy.
 Results During the treatment, no acute reactions were observed. In each case, tumour 
regression over 50% was noted. During the 3 to 14 month follow-up period, com-
plete vaginal tumour regression was seen in 8 of 10 cases.
 Conclusions 500 kHz hyperthermia assisted interstitial brachytherapy can be regarded as effec-
tive and safe procedure, especially when applied as secondary (salvage) treatment. 
More cases and longer observation time are needed to make deﬁ nite conclusions.
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BACKGROUND
Despite diagnostic and therapeutic progress, cer-
vical cancer still has one of the worst epidemio-
logical indices in Poland. Data analysis for the 
year 2000, has shown a morbidity level of 6.8% 
and a mortality level 5.4% for all malignancies. 
During the same period, 3597 new cases of cervi-
cal cancer were diagnosed and 1987 deaths were 
recorded as being caused by this disease [1]. In 
quite a large proportion of patients, because of 
the advanced clinical stage of the disease (IIB-
IIIB according to FIGO), the treatment of choice 
is radiotherapy or radio-chemotherapy with in-
tent to-treat. To reach the optimum dose distri-
bution, the accepted standard is to supplement 
the dose delivered during external beam radio-
therapy, with intracavitary brachytherapy [2]. The 
epidemiological indices for endometrial cancer, 
during the same year were 3276 (6.2% of all ma-
lignancies), and are not so pessimistic. During 
the year 2000, a total of 808 deaths caused by en-
dometrial cancer were noted, which accounts for 
2.2% of all deaths caused by these malignancies. 
Better results of therapy in this case are mainly ow-
ing to less advanced disease which gives the pos-
sibility for radical surgical treatment (and even-
tual adjuvant external beam or brachytherapy) 
[3]. In either of the above mentioned tumour 
sites, there may be some problems with patients 
suffering from relapse in a previously irradiat-
ed ﬁ eld. Co-exisitng conditions and the impos-
sibility of injury avoidance, often exclude surgi-
cal treatment, while the tolerance dose of critical 
organs makes secondary irradiation impossible. 
Improved biological effectiveness from elevated 
temperatures (hyperthermia) on cancer cells and 
the potential of its association with radiotherapy 
is a well known issue. Nevertheless it is not used 
widely enough in oncological practice. The main 
limiting factors are technical difﬁ culties regard-
ing hyperthermia procedures. The problems are 
connected with limited capabilities in obtaining 
therapeutic temperatures (>42.5°C) inside the 
tumour while maintaining healthy tissue protec-
tion. Hyperthermia, used as a complementary 
treatment to radiotherapy provides the possibili-
ty to deliver lower doses with the same biological 
effects. Interstitial brachytherapy may enhance 
this phenomenon by reducing the irradiated vol-
ume and makes it possible to deliver simultane-
ous hyperthermia to the irradiated tissues via the 
same applicators. A unique therapeutic HT-2 set, 
used in the Centre of Oncology, allows the prac-
tical use of hyperthermia in the treatment of cer-
vical and endometrial cancer [4].
MATERIALS
Hyperthermia procedures were performed in 
10 patients: 8 endometrial cancer cases and 2 
cervical cancer patients with early recurrence in 
a previously irradiated ﬁ eld. Hyperthermia was 
combined with interstitial HDR brachytherapy. 
Patients were aged between 46 and 75 years (av-
erage 65). All the patients underwent, prior to re-
currence detection, primary post-operative, exter-
nal beam irradiation (box technique, 46Gy/23fr) 
with the addition of vaginal cuff HDR brachy-
therapy (2–3 × 7,5Gy/fr/0,5cm from the appli-
cator surface).
METHODS
An HT-2 set with a 500 kHz frequency generator 
[4] was used. One or two interstitial hyperther-
mia procedures were performed, using rigid met-
al needles for an HDR Ir-192 source (Gammamed 
12i) and for energy transmission. The total dose 
was 30 Gy, dose per fraction 3 or 6 Gy, and to-
tal treatment time was from 5 to 14 days. In the 
case of 3 Gy per fraction, irradiation was per-
formed twice daily with an interval of at least 8 
hours. Dose distribution calculations were based 
on x-ray needle localizations using the Abacus 
computer planning system. The dose was speci-
ﬁ ed as 0.5–0.7 mm from the needle surface. The 
irradiated volume ranged from 25 to 50 cm3 (av-
erage 30 cm3). For this group of patients, thanks 
to the mobility and the compact size of the HT-2 
set, unique application of brachytherapy during 
the hyperthermia procedure was possible (after 
the therapeutic values of the temperatures were 
obtained, brachytherapy was started, without in-
terruption of the hyperthermia procedure). In 
each case, in order to avoid the thermoresist-
ance effect, the hyperthermia procedure was per-
formed at 48 hours intervals. The total treatment 
time was 45–60 minutes and included at least 45 
minutes with temperatures at up to 46–49°C.
RESULTS
Early sequelae, which may have caused interrup-
tions in treatment, were not observed. In every 
case, irradiation reactions appeared as erythema 
with superﬁ cial subsidence of the epithelium and 
intensiﬁ ed mucous secretion. Rectal and bladder 
reactions were observed in 6 patients but were lim-
ited to grade I, according to the EORTC/RTOG 
scale, and were cured spontaneously. Follow-ups 
were performed one month after treatment and 
every 3 months thereafter. Post-irradiation reaction 
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symptoms disappeared 2–3 months after conserva-
tive treatment (local steroids, vessel wall protectant 
/ oxerutin / anti-infamatory agents / diclofenac). 
No late side-effects were observed. During the fol-
low-up period of 3 to 14 months, complete vagi-
nal tumour regression was conﬁ rmed by clinical 
examination in 8/10 cases. In two cases no regres-
sion was seen. In one case of cervical cancer, a tu-
mour of 4 cm was observed in CT scans before 
treatment. Complete regression of the tumour 
was seen after treatment. This effect lasted for 10 
months. This patient died as a result of sigmoid 
perforation, followed by peritonitis. From the sur-
gical point of view, the observed lesions were lo-
cated outside the re-irradiated volume. The per-
foration was owing to sigmoid occlusion caused by 
adhesions. In a second case, after 5 months follow-
up with complete regression, vaginal recurrence 
(outside the re-irradiated ﬁ eld) and pulmonary 
metastases were detected. In this case, chemo-
therapy according to the PAC scheme (cis-platin, 
adriamycine, cyclophosphamide) was performed. 
Tumour stabilization was observed.
DISCUSSION
The treatment of early recurrence in previously 
irradiated ﬁ elds is not an easy task. The possibil-
ities for surgical treatment are often limited be-
cause of the impossibility of obtaining optimal 
margins without serious injury to the patient (of-
ten colpectomy or ureterotomy). Further irradia-
tion is often impossible owing to risks in exceed-
ing the tolerance doses for healthy tissues. The 
only alternative method is chemotherapy, which 
cannot be regarded as radical treatment. It seems 
that the most interesting possibility for this group 
of patients is the application of hyperthermia as 
a method for strengthening the effects of radia-
tion therapy [5]. Several recently published pa-
pers show a higher index of clinical effectivness 
after incorporating hyperthermia into radiother-
apy. Among the most relevant of these are the re-
sults of the “Dutch Deep Hyperthermia Group”. 
This was a prospective, randomised, multi-centre 
study based on the treatment results of 358 pa-
tients with cervical, rectal or bladder cancers. In 
this group, the 114 patients with cervical cancer 
were divided into two subgroups – 58 patients 
received radiotherapy and hyperthermia and 56 
patients received radiotherapy alone. Local con-
trol rates were 61% and 41% with 3-year survival 
times being 51% and 27% respectively and be-
ing statistically signiﬁ cant. In the subgroup of pa-
tients with rectal cancer (143 patients) no statis-
tically relevant difference was observed. Again, 
the local control rates were respectively 16% and 
8% with 3-year survival times of 22% and 13% re-
spectively. For the 101 patients with bladder can-
cer respective values were 42% versus 33% and 
28% versus 22%[6]. It is very important to note 
that these results were obtained using “external 
heating” which is not so effective as intracavitary 
heating due to treatment intolerance and a low-
er range of temperatures.
In a randomised trial by Harima et al, assessing 
the concentration of Bax and Bcl-2 proteins in 
irradiated cervical carcinoma cells, signiﬁ cant-
ly different protein concentrations were found 
when treatment by hyperthermia and radiother-
apy was compared with radiotherapy alone. This 
was positively correlated with the percentage of 
complete tumour regression (83.3% in the hyper-
thermia combined group vs. 52.6% in the radio-
therapy alone group). A negative correlation was 
observed with lack of response (5.6% vs. 21.1% 
respectively) [7].
Vasanthan et al. found no beneﬁ ts from the addi-
tion of hyperthermia to radiotherapy in cervical 
cancer patients. It should be pointed out that the 
temperatures achieved in this study were in many 
cases signiﬁ cantly lower than needed minimum 
of 42.5°C [8]. Being multi-centered, this study 
included a very limited number of patients from 
each institution (1–27) and irradiation was per-
formed in a non-uniform manner. The hyperther-
mia procedure was performed using different ma-
chines and using different protocols. Temperature 
measurements were not performed in more than 
50% of the hyperthermia sessions. With respect 
to the increasing efﬁ ciency of radiotherapy, lim-
itation of the total dose and avoidance of late se-
quelae are possible. An interesting observation 
was made by Van der Zee et al. [9] while evalu-
ating post-irradiation injuries in post mastecto-
my breast cancer patients, treated for scar recur-
rence. Two adjacent regions of the thoracic wall 
were irradiated with the same dose. The differ-
ence between these areas was the addition of si-
multaneous hyperthermia to irradiation therapy 
in one ﬁ eld. As a result, signiﬁ cantly fewer signs 
of telangiectasia were observed in hyperthermia 
treated ﬁ elds. Authors associate this with faster 
sub-lethal injury repairs to intraepithelial cells 
damaged during irradiation. In their study, Li et 
al. [10], treating breast cancer patients with recur-
rence, conﬁ rmed a higher percentage of complete 
remissions in previously irradiated ﬁ elds when 
hyperthermia was added. Even signiﬁ cantly low-
er doses (43 Gy in radiotherapy + hyperthermia 
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group vs. 59.5 Gy in radiotherapy alone group), 
were more effective when hyperthermia was ap-
plied. In a recently published paper, Kouloulias 
et al. showed a higher sphincter preservation rate 
(95.8% radiotherapy + hyperthermia vs. 68.0% 
radiotherapy alone) when hyperthermia was add-
ed to the standard radio-chemotherapy of anal 
cancer patients [11].
With respect to the necessarily high radiation dos-
es used in gynaecological malignancies, hyper-
thermia provides a means to limit radiation in-
duced injuries. This fact is crucial in the case of 
re-irradiation. Studies with practical hyperther-
mia application, performed over several years 
at Centre of Oncology in Warsaw [4,12], con-
ﬁ rmed its biological effect and proves its prac-
tical usefulness. In particular, simultaneous in-
terstitial brachytherapy and hyperthermia allows 
us to take maximum advantage of the combina-
tion of both methods [13,14]. To date, howev-
er, the results presented above refer to a small 
group of patients with relatively short follow-up. 
Nevertheless, on this basis we may take advan-
tage of the therapeutic potential of simultane-
ous hyperthermia and radiotherapy.
CONCLUSIONS
A 500 kHz hyperthermia assisted interstitial brachy-
therapy can be regarded as effective and safe proce-
dure, specially when applied as secondary (salvage) 
treatment. More cases and longer observation time 
are needed to make deﬁ nite conclusions.
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Summary
 Background The conformal radiotherapy technique is a particularly important method for 
the treatment of children with localized low-grade brain tumours, whose prog-
nosis, with regard to long-term survival is often excellent and should be accom-
panied by the smallest possible risk of toxicity. 
 Aim The results of 3-D conformal radiotherapy in children with low-grade astrocyto-
ma and craniopharyngioma, treated in our department to present.
 Materials/Methods Between 1997–2001, 20 children, aged between 3.5 and 18 years, with low-grade 
brain tumours (8 craniopharyngioma and 12 low-grade astrocytoma) were treat-
ed with conformal radiotherapy. In the craniopharyngioma group, all patients 
were irradiated owing to tumour recurrence, after multiple surgeries, and were 
seriously handicapped before the commencement of radiotherapy. Patients with 
astrocytoma were treated after chemotherapy, partial surgery or biopsy only.
 Results All patients with craniopharyngioma survived with no recurrence (5) or with a 
stable disease state (3). Radiation related complications were not observed. Four 
patients with astrocytoma died, due to progressive disease (3) or chemotherapy 
related complications (1). Two patients are living with dissemination to the CNS, 
4 with no recurrence and 2 have stabilized. Late complications after radiothera-
py were not observed.
 Conclusions Three-dimensional radiation therapy is a safe and successful method for the com-
bined treatment of children with low-grade brain tumours. The risk of radiother-
apy related complications is relatively low.
 Key words conformal radiotherapy • brain tumours • craniopharyngioma • astrocytoma • 
children
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BACKGROUND
CNS tumours constitute approximately 20% of 
all paediatric neoplasms. Low-grade astrocytomas 
account for nearly one-half of all brain tumours 
in children. They are a heterogenous group of 
tumours, with an overall survival rate as high as 
80–100%. Craniopharyngiomas represent less 
than 10% of intracranial neoplasms in children 
and adolescents and one half of sellar tumours. 
Despite recent progress in neurosurgery and de-
velopment of new chemotherapy protocols, ra-
diotherapy is still an important method in the 
treatment of CNS tumours in children [1].
Conformal radiotherapy techniques are per-
formed using multiple treatment ﬁ elds, each 
shaped to conform to a “beam’s eye” view of 
the target volume. This allows for a high ho-
mogenous dose of irradiation to be delivered 
to the tumour region while minimising the 
doses to normal tissue. This is particularly im-
portant for children with localized low-grade 
brain tumours whose prognosis regarding long-
term survival is often excellent and should be 
accompanied by the smallest possible risk of 
toxicity [2,3].
AIM
The aim of this work was to present the results 
of three-dimensional conformal radiotherapy in 
children with low-grade brain tumours, treated 
in our department.
MATERIALS AND METHODS
Between 1997 and 2001, 20 children, aged 3.5–18 
years, 8 with craniopharyngioma and 12 with low-
grade astrocytoma, were treated with conformal 
radiotherapy techniques in our Radiotherapy 
Department. Neurosurgery and chemothera-
py were carried out in the Children’s Memorial 
Health Institute in Warsaw.
All patients with craniopharyngioma were re-
ferred to radiotherapy, due to tumour recurrence 
after multiple surgeries, and were seriously hand-
icapped before the onset of radiotherapy.
Patients with astrocytoma were treated after par-
tial surgery (3) or biopsy only (9) or after chem-
otherapy (7).
Radiotherapy was delivered using a linear accel-
erator with an energy of 6 or 15 MV. The total 
dose at the ICRU reference point was 54 Gy in 
30 fractions for all patients.
Orﬁ t masks were used for head immobilisation 
in all cases. After preliminary simulations, the pa-
tients underwent CT examinations in their treat-
ment position. The 3-D treatment planning was 
performed with a 3-D treatment planning system, 
TMS-Helax. The gross tumour volume (GTV) in-
cluded the tumour itself or the tumour bed with 
residual tumour. The CTV included the GTV with 
an added margin of 1.0 cm. The planning tar-
get volume (PTV) included the CTV surround-
ed by an additional margin of 0.5 cm in three 
dimensions.
Beam position, dimensions and shape were 
planned using the beams eye view. All patients 
were treated by an isocentric technique, using 
photon beams generated by a Megatron KD2 ac-
celerator (Siemens). Most patients were treated 
with three or more noncoplanar ﬁ elds. The irra-
diated volume was matched to the planned vol-
ume by using individual blocks. Three-dimen-
sional dose distributions were calculated with the 
help of our TPS. Minimal, maximal and average 
doses to the PTV as well as the maximal dose to 
organs of risk was reported, together with dose-
volume histograms. Simulations of the treatment 
plan were performed using an Oldelft simulator, 
and simulator radiographs were produced. The 
post veriﬁ cation ﬁ lms were taken during the ﬁ rst 
irradiation. The portals were compared with sim-
ulator ﬁ lms and the DRRs by a dedicated compu-
ter program. In most cases (90%), no correction 
of ﬁ eld position or shielding was required.
Neurologic/hormonal late complications of ra-
diotherapy were graded according to the Bloom 
scale (4).
RESULTS
The observation period was closed on the 
31.01.2003. The median time of follow up, from 
commencement of radiotherapy until the last ob-
servation, was 48 months (from 4 to 80).
All patients with craniopharyngioma are living 
with no recurrence (5) or with a stable disease 
state (3). No radiotherapy related complications, 
according to the Bloom scale, were observed.
Four patients with astrocytoma died. In 3 patients, 
progression of nonoperable tumours after 6, 9 
and 12 months occurred. Those patients survived 
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from 1 to 13 months. One died owing to compli-
cations of chemotherapy. Two are living with me-
tastases to the supratentorial and spinal regions, 
diagnosed 6 and 16 months post radiotherapy. 
Both were treated for the stabilisation of symp-
toms using multiagent chemotherapy regimes 
including: Adriamycin, Ifosfamid and Vepesid. 
Four children are living with no recurrence and 
2 have stabilized, as conﬁ rmed by MRI.
No late complications of radiotherapy, evaluated 
according to the Bloom scale, were observed.
Patient status and treatment results are present-
ed in Tables 1 and 2.
DISCUSSION
Conformal radiotherapy techniques as 3-D con-
formal radiotherapy, or stereotactic radiotherapy 
for smaller tumours, have become the standard 
for the care of children and adults with relative-
ly noninvasive intracranial tumours.
For patients after subtotal resection of crani-
opharyngioma, 3-D conformal radiotherapy or 
more precise techniques, such as stereotactic 
radiotherapy, were widely applied. Results from 
those treatment methods are excellent, with 5–10 
year overall and disease-free survival rates as high 
as 90% and 80% respectively [5–9]. In most ex-
pert opinions, external irradiation should be ap-
plied early in the treatment course, and follow-
ing limited surgical resection, in order to limit 
the severe toxicity that has been reported follow-
ing maximal tumour resection and repeated sur-
geries [10,11]. In our material, all patients with 
craniopharyngioma were refered for radiother-
apy owing to tumour recurrence after multiple 
surgeries and were seriously handicapped before 
radiotherapy began.
In the St. Jude Children’s Research Hospital, 
experience with paediatric patients treated for 
craniopharyngioma showed that children treat-
ed by surgery lost a mean of 9.8 points on the 
IQ scale while those treated using combined-mo-
No Sex
Age at time 
of diagnosis 
(years)
Surgery 
(year) Status before RT
Age at time 
of RT RT (year) Present status
Follow up 
(months)
1 M  4 19951997
Hypophysis insuﬀ .
Partially blind  6 1992
NED
Hypophysis insuﬀ . HRT
Partially blind
78
2 F  3 19881990
Hypophysis insuﬀ .
Totally blind  12 1997
SD
Hypophysis insuﬀ .
Osteoporosis, HRT
Totally blind
67
3 M  5
1996
1996
1998
Hypophysis insuﬀ .
Partially blind  7 1998
SD
Hypophysis insuﬀ . HRT
Partially blind
60
4 M  13 19971999
Hypophysis insuﬀ .
Diabetes insipidus  15 1999
NED
Hypophysis insuﬀ . HRT 48
5 F  3 19961999
Pubertas praecox
Hypophysis insuﬀ .  5 1999
NED
Hypophysis insuﬀ .
HRT
48
6 M  5 19971999 Hypophysis insuﬀ .  8 2000
NED
Hypophysis insuﬀ . HRT 44
7 M  4
1996
1997
1998
Hypophysis insuﬀ .
Totally blind  8 2001
SD
Hypophysis insuﬀ . HRT
Totally blind
32
8 F  4 19972001
Hypophysis insuﬀ .
HRT  7 2001
NED
Hypophysis insuﬀ . HRT 32
Table. 1. Craniopharyngioma patients – characteristics and treatment results.
NED – no evidence of disease; SD – stable disease; HRT – hormone replacement therapy; RT – radiotherapy.
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dalities lost only 1.25 points. Patients in the sur-
gery group, who had relapses, lost a mean of 13.1 
points. The loss of 10 points was considered to 
be clinically signiﬁ cant. The surgery group also 
had more frequent neurologic, opthalmic and 
endocrine complications [7]. These ﬁ ndings are 
in agreement with our data, wherein 4 children 
were partially or totally blind following repeated 
surgical procedures.
It has now been established that limited surgery 
and radiotherapy cause lesser or comparable con-
sequences. Newer radiation planning and deliv-
ery techniques have made combined modality a 
good initial option for most patients with crani-
opharyngioma.
For most children with low-grade astrocytoma, 
the treatment of choice is surgery. Complete re-
section rates are approximately 80% for hem-
ispheric and cerebellar tumours and 40% for 
diencephalic tumours. Complete or subtotal re-
section leads to long term disease-free survival 
in more than 80% of children [12]. These pa-
tients are recommended to continue under sur-
veillance alone [13]. Radiotherapy might be ben-
eﬁ cial for patients with bulky residual tumours 
or with deep midline tumours that are surgically 
inaccessible. The overall survival rates for those 
patients range between 33% and 75% at 10 years 
[12]. Stereotactic irradiation techniques and 3-D 
conformal radiotherapy are well established in 
adults, but data regarding childhood low-grade 
gliomas is scarce [14].
Merchant et al. treated 38 children with fraction-
ated conformal radiotherapy and, after a median 
follow-up of 17 months, only 4 tumours relapsed. 
Acute toxicity was low [15]. Saran treated 14 chil-
dren with conformally guided stereotactic radio-
Table 2. Astrocytoma patients – characteristics and treatment results.
No Sex
Age
at time
of diagnosis
Surgery (year) Chth
RT Status before 
RT Present status
Follow up 
(months)
Year Age
1 M  9 1996 (partial) No 1997  9 No deﬁ cits NEDNo deﬁ cit  80
2 M  14 1997 (biopsy) No 1997  14 Epilepsy Progression 1998DDD 1999  +20
3 M  10 1997 (biopsy) No 1997  10 HemiparesisN.VII paresis
NED
No deﬁ cit  78
4 F  6 1997 (biopsy) Yes (progression) 1997  6 Somnolence DDD 1998  +12
5 M  13
1993 (part)
1994 (part)
1998 (shunt)
Yes 1998  18 Visual deﬁ citsQuadriparesis
Dissemination (chemotherapy)
LWD  60
6 F  10 1998 (biopsy) No 1998  10 N.VI paresis DDD 1999  +12
7 M  14 1998 (biopsy) Yes 1999  15 EpilepsyN.VI paresis
Dissemination (chemotherapy)
LWD  48
8 F  11 1993 (part)1998 (part) Yes (progression) 1999  17 Ataxia DDC (chemotherapy related)  +2
9 M  3 1988 (part)1999 (part) No 1999  14 N.VI paresis NED  50
10 M  2 1994 (partial) Yes 1999  6 Hypophysis insuﬀ . SDHypophysis insuﬀ .  50
11 F  2 1998 (biopsy) Yes (progression) 1999  3.5 No deﬁ cits NEDThyroid insuﬀ . HRT  48
12 M  5 1999 (partial) Yes (progression) 1999  5 Nystagmus SD  46
NED – no evidence of disease; SD – stable disease; LWD – living with disease; DDD – died due to disease; DDC – died due to complications; 
HRT – hormone replacement therapy.
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therapy and achieved a 3-year local progression-
free survival rate of 87%, and an overall survival 
rate of 100%. Four of 12 children with neurological 
deﬁ cits improved while 5 remained stable [16].
In our data, radiotherapy was applied in the cases 
of 12 children with low-grade astrocytoma after 
partial resection or biopsy only. Four of these pa-
tients are living with no evidence of disease and 
2 with MRI proven, stable disease.
The occurrence of metastatic disease in the CNS 
for low-grade astrocytoma is a rare event and oc-
curs in only 5–10% of cases. With improvements 
in neuroimaging, this phenomenon is being re-
ported with increasing frequency, and as a con-
sequence, craniospinal irradiation needs to be 
considered for these patients [14]. In our mate-
rial, 2 patients are living with dissemination in 
the CNS, diagnosed 6 and 16 months after ra-
diotherapy. Both were successfully treated with 
salvage chemotherapy, including Adriamycin, 
Ifosfamid, Vepesid.
The role of chemotherapy in the treatment of 
patients with low-grade astrocytoma should be 
established. Platinum based chemotherapy ap-
plied in young (<5 years) children with symp-
tomatic hypothalamic and chiasmatic tumours, 
delays the use of irradiation. For older sympto-
matic patients conformal radiotherapy remains 
the standard therapy [17]. In our material, 7 chil-
dren were treated initially by chemotherapy while 
4 progressed and one died due to an adjuvant 
chemotherapy related complication.
The use of local irradiation alone did not signiﬁ cant-
ly effect IQ scores over time. The tumour itself is an 
important cause of patient’s decline in IQ, and is 
more often observed in younger patients [17,18].
Up to the present time, we have not observed any 
late complications related to radiotherapy, though 
longer follow-up periods are necessary.
CONCLUSIONS
Three-dimensional radiation therapy is a safe 
and successful method for the combined treat-
ment of children with low-grade brain tumours. 
Radiotherapy should be applied early in the course 
of treatment for patients with craniopharyngioma 
and following limited surgical resection to avoid 
severe toxicity of repeated surgery. Conformal 
radiotherapy is the treatment of choice for pa-
tients with astrocytoma, when total resection of 
tumour is not possible. The risk of radiotherapy 
related complications is relatively low.
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